Bernardo Queralt

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial

Eduardo Díaz‐Rubio, Josep Tabernero, Auxiliadora Gómez‐España et al. · Journal of Clinical Oncology · 2007 · 269 citations · Full text

Medicine, Oncology, Pharmacology +11

Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study

Marta Martín-Richard, R. Gallego, Carles Pericay et al. · Investigational New Drugs · 2013 · 82 citations

Medicine, Oncology, Pharmacology +11

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Cristina Grávalos, Carlos Gómez-Martín, Fernando Rivera et al. · Clinical & Translational Oncology · 2011 · 80 citations

Medicine, Oncology, Pharmacotherapy +17

Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells

Cristina Oliveras‐Ferraros, Sílvia Cufí, Bernardo Queralt et al. · British Journal of Cancer · 2012 · 59 citations · Full text

Medicine, Molecular Biology, Oncology +17

Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study

Javier Sastre, Enrique Aranda, Bartomeu Massutí et al. · Critical Reviews in Oncology/Hematology · 2008 · 50 citations

Medicine, Geriatric Medicine, Oncology +11